09 June 2000
Post-TransplanIt Immune Serological Markers May Be Predictive of Chronic Rejection
Ronald H KermanAnn Transplant 2000; 5(2): 24-28 :: ID: 497522
Abstract
Chronic rejection isan important cause ofgraft dysfunction and loss after the first posttransplant year [1].Two working hypotheses have evolved to explainthe etiology of the process. The first is an antigen-dependent phenomenon influenced by early immunological injury whereas the second is related to alloantigen-independent events contributing to progressive chronic graft dysfunction [2,3]. Our study, reported herein, focuses on the antigen-dependent aspects of chronic rejection. Several hypotheses have been proposed to explain the immunologic basis of chronic rejection. The first involvesrecurrent episodes of acute rejection that lead to protracted tissue damage and scarring [2,3].An alternative immune hypothesis to explain chronic rejection is that the immune-regulatory mechanisms that prevent acute rejection playa role in chronic rejection by supporting B cell responses and antibody formation. Therefore, chronic rejection may be a predominantly antibody- mediated form of graft damage..
Keywords: post-transplant antibody, chronic rejection
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






